AID expression in B-cell lymphomas causes accumulation of genomic uracil and a distinct AID mutational signature  by Pettersen, Henrik Sahlin et al.
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The  most  common  mutations  in  cancer  are  C to T transitions,  but  their  origin  has  remained  elusive.
Recently,  mutational  signatures  of  APOBEC-family  cytosine  deaminases  were  identiﬁed  in  many  com-
mon cancers,  suggesting  off-target  deamination  of cytosine  to uracil  as a common  mutagenic  mechanism.
Here  we  present  evidence  from  mass  spectrometric  quantitation  of deoxyuridine  in DNA  that  shows  sig-
niﬁcantly  higher  genomic  uracil content  in  B-cell  lymphoma  cell  lines  compared  to non-lymphoma  cancer
cell  lines  and  normal  circulating  lymphocytes.  The  genomic  uracil  levels  were  highly  correlated  with  AID
mRNA  and protein  expression,  but not  with  expression  of other  APOBECs.  Accordingly,  AID knockdown
signiﬁcantly  reduced  genomic  uracil content.  B-cells  stimulated  to express  endogenous  AID  and  undergo
class  switch  recombination  displayed  a several-fold  increase  in  total genomic  uracil, indicating  that  B
cells  may  undergo  widespread  cytosine  deamination  after  stimulation.  In  line  with  this,  we  found  thatase excision repair
ataegis
utational signature
clustered  mutations  (kataegis)  in  lymphoma  and  chronic  lymphocytic  leukemia  predominantly  carry
AID-hotspot  mutational  signatures.  Moreover,  we observed  an  inverse  correlation  of genomic  uracil  with
uracil  excision  activity  and  expression  of the uracil-DNA  glycosylases  UNG  and  SMUG1.  In  conclusion,
AID-induced  mutagenic  U:G  mismatches  in  DNA  may  be  a fundamental  and  common  cause  of  mutations
in  B-cell  malignancies.
ublis©  2014  The  Authors.  P
. Introduction
The only sources of uracil in DNA were previously thought
o be misincorporation of dUMP during DNA replication and
pontaneous deamination of DNA cytosine. The discovery of
ctivation-induced cytidine deaminase (AID, also called AICDA) and
everal other APOBEC-family enzymes as probable DNA-cytosine
eaminases introduced a third possible source (reviewed in [1]).
∗ Corresponding authors. Tel.: +47 72 57 30 74/+47 72 573221;
ax: +47 72 57 64 00.
E-mail addresses: bodil.kavli@ntnu.no (B. Kavli), hans.krokan@ntnu.no
H.E. Krokan).
1 Present address: Science for Life Laboratory, Division of Translational Medicine
nd Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolin-
ka Institutet, S-17121 Stockholm, Sweden.
ttp://dx.doi.org/10.1016/j.dnarep.2014.11.006
568-7864/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unhed  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
AID was ﬁrst identiﬁed following induction of class switch recom-
bination (CSR) in the CH12 mouse B-cell lymphoma cell line and
initially thought to be an RNA-editing enzyme [2]. However, evi-
dence that AID was a DNA mutator in Escherichia coli [3] and its
functional interaction with uracil-DNA glycosylase UNG in adaptive
immunity [4–6], indicated that AID is a DNA-cytosine deaminase.
Later several of the other known APOBEC-family enzymes were
also found to be DNA-cytosine deaminases in vitro [7,8]. DNA cyto-
sine deamination by APOBEC-family enzymes is a natural event in
both the adaptive and innate immune systems, through targeted
deamination of immunoglobulin (Ig) genes by AID and deamina-
tion of viral DNA by APOBEC enzymes, respectively [7]. Despite their
important physiological functions, these host defense mechanisms
entail a high risk of potentially carcinogenic off-target genomic
mutagenesis. Recent high-throughput sequencing of large num-
bers of human cancer genomes showed that mutations at cytosine
residues, particularly C to T transitions, are the most prevalent
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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phase column (2.1 mm × 150 mm,  3.5 m,  Zorbax SB-C18, Agilent
Technologies), using a water/methanol gradient containing 0.1%
formic acid on an API5000 triple quadrupole mass spectrometerH.S. Pettersen et al. / D
utations in human cancer, highlighting enzymatic deamination of
ytosine to uracil as a potential source of mutagenesis [9–11]. How-
ver, the actual uracil level in normal and various cancer genomes
as remained elusive.
Here, a sensitive LC/MS/MS-based method for quantiﬁcation
f genomic 2′-deoxyuridine (dUrd) was applied to demonstrate
hat B-cell lymphoma cell lines contain several-fold increased lev-
ls of genomic uracil compared to normal human lymphocytes
nd non-lymphoma cell lines. Genomic uracil content correlated
ith AID protein expression but not with other APOBEC enzymes.
n accordance with AID-generated uracil, we found that regions
f clustered mutations (kataegis) in lymphoma and chronic lym-
hocytic leukemia (CLL) have a distinct AID-hotspot mutational
ignature. Importantly, we also show that uracil excision capac-
ty and expression of the uracil-DNA glycosylases UNG and SMUG1
orrelated negatively with genomic uracil levels and to some extent
iminished the effect of AID. This study provides direct mechanistic
vidence for genomic uracil accumulation due to enzymatic DNA
ytosine deamination in human cancers.
. Materials and methods
.1. Primary cells, cell lines, cultivation, and reagents
Human cell lines HeLaS3 (ATCC CCL-2.2TM), HEK293T (ATCC
RL-11268TM), and U2OS (ATCC HTB-96TM) were from ATCC. L428
DSMZ ACC 197), DU145 (DSMZ ACC 261), KARPAS422 (DSMZ
CC 32), T24 (DSMZ ACC 376), DOHH2 (DSMZ ACC 47), SUDHL4
DSMZ ACC 4956), JJN3 (DSMZ ACC 541), SUDHL5 (DSMZ ACC 571),
UDHL6 (DSMZ ACC 572 6), RAMOS (DSMZ ACC 603), RL (DSMZ
CC 613), DAUDI (DSMZ ACC 78 5), A431 (DSMZ ACC 91) were
rom DSMZ. OCILY3 was a gift from Dr. L.M. Staudt, Metabolism
ranch, Center for Cancer Research, National Cancer Institute,
ational Institutes of Health, Bethesda, MD,  USA. Peripheral blood
ononuclear cells (PMBCs) were puriﬁed from buffy coats from
hree healthy blood donors using the LymphoprepTM (Progen) kit
ccording to the manufacturer’s protocol. Human B-lymphocytes
ere puriﬁed from buffy coats from three healthy blood donors
sing a negative selection kit from StemCell Technologies accord-
ng to the manufacturer’s protocol. HeLaS3, HEK293T, T24, A431,
U145, and U2OS cells were cultured in DMEM (4500 mg/l glu-
ose) with 10% FCS, 0.03% l-glutamine, 0.1 mg/ml gentamicin and
.3 g/ml fungizone at 37 ◦C and 5% CO2. DAUDI, DOHH-2, KARPAS,
AMOS, SU-DHL-4, SU-DHL-6, OCILY-3, L-428, RL, SU-DHL-5, and
JN3 cells were cultured in RPMI-1640 with 4500 mg/l glucose,
.03% l-glutamine, Pen-Strep (1×  ﬁnal), 0.1 mg/ml  gentamicin, and
.3 g/ml fungizone, and 20% heat inactivated (56 ◦C, 20 min) FCS at
7 ◦C and 5% CO2. For quantitative rtPCR and uracil measurements
ells were harvested at densities between 750 000 and 2 million
ells/ml.
Cell doubling times for suspension cells were measured using
 Countess® cell counter (Invitrogen) by two parallel daily mea-
urements for three to ﬁve day periods from cell densities of
0 000–200 000 cells/ml to one to three million cells/ml. For adher-
nt cells, doubling time was measured in 96 well plates (3–6 parallel
ells; starting density 50 000 cells/ml) for a three day period by
aily ﬂuorescent measurement of resazurin (Sigma) metabolism
ccording to the manufacturer’s protocol. Doubling times were cal-
ulated by exponential regression.
SUDHL5 AID knockdown and control cells were made using
pen Biosystem TransLenti Viral Packaging Mix, pTRIPZ AICDA
hRNA (RHS4741-EG57379; vectors V2THS 58282, 58283, and
8319) or pTRIPZ non-silencing control vector according to the
anufacturer’s protocol. Brieﬂy, lentiviruses were produced in
EK293T cells, and then supernatant from three consecutive dayspair 25 (2015) 60–71 61
48 h after HEK293T transfection were used to infect SUDHL5 cells.
Infected SUDHL5 cells were ampliﬁed for another 48 h and then
selected with 2 g/ml puromycin for 30 days. Expression was
induced with 1 g/ml doxycycline.
CH12F3 AID-EYFP and EYFP stable transfectants, confo-
cal microscopy, and stimulation experiments were described
previously [12]. CH12F3 cells (2 × 106 cells/ml) were cul-
tured in RPMI medium, with 10% heat-inactivated fetal calf
serum, 0.03% l-glutamine, 50 M -mercaptoethanol, 1 mM Na-
pyruvate, 0.1 mg/ml  penicillin/streptomycin, 2.3 g/ml fungizone,
and 1.0 mg/ml  G418. CH12F3 cells were stimulated to undergo
class switch recombination by adding 10 ng/ml mouse recom-
binant IL-4 (Peprotech), 2 g/ml anti-mouse CD40 monoclonal
antibody (BD Biosciences) and 1 ng/ml human TGF-1 (Pepro-
tech) and harvested 48 h post stimulation for DNA and protein
isolation. Western analysis of AID protein expression was per-
formed using mouse anti-AID monoclonal antibody no. 39-2500,
clone ZA001, 500 g/ml (Invitrogen). Nuclear extracts from syn-
chronized HeLa cells were prepared essentially as described
[13,14].
2.2. RNA isolation and quantitative real-time PCR (qRT-PCR)
Total RNA for mRNA analysis was  prepared using the mirVana
miRNA isolation kit (Ambion) according to the manufacturer’s
instructions. RNA concentration and quality was measured on a
NanoDrop ND-1000 UV–vis spectrophotometer. Total RNA (770 ng)
was reverse transcribed for gene expression analysis using Taq-
Man  reverse transcription reagents (Applied Biosystems). The
following TaqMan gene expression assays (Applied Biosystems)
were used: AID (Hs00757808 m1), UNG (Hs00422172 m1),
SMUG1 (Hs04274951 m1), TDG (Hs00702322 s1), MBD4
(Hs00187498 m1), APOBEC1 (Hs00242340 m1), APOBEC2
(Hs00199012 m1), APOBEC3A (Hs00377444 m1), APOBEC3B
(Hs00358981 m1), APOBEC3C (Hs00819353 m1), APOBEC3D
(Hs00537163 m1), APOBEC3G (Hs00222415 m1), APOBEC3F
(Hs01665324 m1), APOBEC3H (Hs00419665 m1), APOBEC4
(Hs00378929 m1), and GAPDH (Hs99999905 m1). Quantitative
PCR was carried out on a Chromo4 (BioRad) real-time PCR detec-
tion system. Relative expression of mRNA was calculated by the
Ct method using GAPDH as endogenous control. Regression
analyses were done using GraphPad Prism where data were ﬁtted
by linear regression (log/linear(X) vs. log/linear(Y)) as indicated.
2.3. Quantiﬁcation of uracil in DNA by LC/MS/MS
Genomic uracil was quantiﬁed as previously described
[15]. Brieﬂy, DNA was  isolated by phenol:chloroform:isoamyl
extraction, treated with alkaline phosphatase to remove free
deoxyribonucleosides, and then enzymatically hydrolyzed to
deoxyribonucleosides. Deoxyuridine (dU) was then separated
from deoxycytidine (dC) by HPLC fractionation using a reverse-
phase column with embedded weak acidic ion-pairing groups
(2.1 mm × 150 mm,  5 m,  Primesep 200, SIELC technologies), using
a water/acetonitrile gradient containing 0.1% formic acid. The dU
fraction was  ﬁnally analyzed by ESI-LC/MS/MS using a reverse(Applied Biosystems) in positive ionization mode. A small frac-
tion of the hydrolyzed deoxyribonucleosides were quantiﬁed by
LC/MS/MS in parallel and used to determine the amount of dU per
106 deoxyribonucleosides.
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.4. In vitro uracil DNA excision activity and complete BER assays
Standard UDG activity assay was performed as described [16].
rieﬂy, 20 l reaction mixtures containing (ﬁnal) 1.8 M nick trans-
ated [3H]-dUMP-labeled calf thymus DNA (U:A substrate), 1× UDG
uffer (20 mM Tris–HCl, pH 7.5, 60 mM NaCl, 1 mM DTT, 1 mM
DTA, 0.5 mg/ml  BSA) and 1 g whole cell extract were incubated at
0 ◦C for 10 min. Acid-soluble [3H] uracil was quantiﬁed by scintil-
ation counting. Whole cell extracts was prepared as described [17].
ligodeoxynucleotide UDG assays were performed as described
16]. Brieﬂy, double-stranded DNA substrates were generated by
nnealing 6-FAM-labeled oligonucleotides containing a centrally
ositioned uracil in an AID-hotspot (5′-CATAAAGAGUTAAGCCTGG-
′; Eurogentec) to complementary strands containing G opposite
. Activity was measured in 10 l assay mixtures containing (ﬁnal)
0 nM substrate, 1× UDG buffer and 0.4 g cell extract, and incu-
ated at 37 ◦C for 10 min. Reactions were stopped and AP-sites were
leaved by addition of 50 l 10% piperidine followed by incubation
t 90 ◦C for 20 min. Product and substrate were separated on PAGE,
canned on Typhoon Trio imager and quantiﬁed using ImageQuant
L software (GE healthcare).
BER assays were carried out essentially as described [14,17].
rieﬂy, 10 g nuclear extract was incubated with 250 ng cccDNA
covalently closed circular DNA) substrates in ﬁnal concentra-
ions of 40 mM HEPES-KOH, 70 mM KCl, 5 mM MgCl2, 0.5 mM DTT,
 mM ATP, 20 M dATP, 20 M dGTP, 20 M dTTP, 8 M dCTP,
.4 mM phosphocreatine, 62.5 ng/l creatine kinase and 50 nCi/l
-32P]dCTP in a ﬁnal volume of 40 l. Reactions were incubated
or 25 min  at 37 ◦C and stopped by addition of EDTA (18 mM ﬁnal)
nd 6 g RNaseA and incubated at 37 ◦C for 10 min  followed by
he addition of SDS (0.5% ﬁnal) and 12 g proteinase K. DNA was
xtracted by phenol/chloroform and precipitated in ammonium
cetate/ethanol and digested with XbaI and HincII (New England
iolabs). Following 12% PAGE, bands were visualized and quanti-
ed using ImageQuant software (Fujiﬁlm). We  investigated relative
ontribution of SMUG1, TDG and UNG2 to the initiation of uracil
epair by pre-incubating extracts with neutralizing antibodies to
MUG1 (0.11 g/l  ﬁnal concentration), UNG (0.3 g/l  ﬁnal con-
entration), and/or neutralizing anti-serum towards TDG (1:50
ilution) on ice for 30 min  prior to the reaction.
.5. Flow cytometric analysis of cell cycle
Cells were ﬁxed in 70% methanol, washed twice with PBS,
nd then treated with 50 l RNaseA (100 g/ml in PBS) at 37 ◦C
or 30 min  prior to DNA staining with 200 l propidium iodide
50 g/ml in PBS) at 37 ◦C for 30 min. Cell cycle analyses were per-
ormed using a FACS Canto ﬂow cytometer (BD-Life Science).
.6. Sample preparation and targeted mass spectrometry
Cell pellets were resuspended in 1× packed cell volume in
uffer I: 10 mM Tris–HCl pH 8.0, 200 mM KCl, 1× complete protease
nhibitor, and 5× phosphatase-inhibitor cocktails I and II (Sigma-
ldrich), 10 M suberoylanilide hydroxamic acid (SAHA) (Cayman
hemicals) and 0.05 M,  Ubiquitin Aldehyde (Biomol International
P) followed by addition of an equal ﬁnal volume of buffer II: 10 mM
ris–HCl pH 8.0, 200 mM KCl, 10 mM EGTA, 10 mM MgCl2, 40%
lycerol, 0.5% NP40, 1 mM DTT, 1× complete protease inhibitor,
nd 5× phosphatase-inhibitor cocktails I and II (Sigma-Aldrich),
0 M suberoylanilide hydroxamic acid (SAHA) (Cayman chemi-
als) and 0.05 M,  Ubiquitin Aldehyde (Biomol International LP)
ontaining an endonuclease cocktail of 200 U Omnicleave (Epicen-
er Technologies), 2 U DNase I (Roche Inc.), 250 U Benzonase (EMD),
00–300 U micrococcal nuclease (Sigma-Aldrich), and 10 g RNase
 (Sigma-Aldrich) per 1 ml  of buffer II. After resuspension, thepair 25 (2015) 60–71
lysates were incubated for 1.5 h at 4 ◦C in a roller. 50 g protein
of cell lysate pools consisting of 2–4 biological replicates from each
cell line were incubated with 5 mM tris (2-carboxyethyl) phosphine
(TCEP) for 30 min  followed by alkylation with 1 mol/mg protein
of iodoacetamide for 45 min  in the dark. Proteins were precipitated
using a methanol–chloroform method as described [18], including
another round of reduction and alkylation prior to overnight diges-
tion with Trypsin (Promega) at 1:40 ratio (w/w, enzyme:protein)
at 37 ◦C. Tryptic digests were dried out, resuspended in 0.1% formic
acid and analyzed on a Thermo Scientiﬁc QExactive mass spec-
trometer operating in Targeted-MS2 mode coupled to an Easy-nLC
1000 UHPLC system (Thermo Scientiﬁc/Proxeon). Peptides (2 g)
were injected onto a Acclaim PepMap100 C-18 column (75 m
i.d. × 2 cm,  C18, 5 m,  100 A˚) (Thermo Scientiﬁc) and further sep-
arated on a Acclaim PepMap100 C-18 analytical column (75 m
i.d. × 50 cm,  C18, 3 m,  100 A˚) (Thermo Scientiﬁc). A 120 min
method was used and consisted of a 300 nl/min ﬂow rate, start-
ing with 100% buffer A (0.1% Formic acid) with an increase to 5%
buffer B (100% Acetonitrile, 0.1% Formic acid) in 2 min, followed by
an increase to 35% Buffer B over 98 min  and a rapid increase to 100%
buffer B in 6 min, where it was  held for 5.5 min. The solvent compo-
sition was  quickly ramped to 0% buffer B, where it was subsequently
held for 8 min  to allow the column to equilibrate for the next run.
The peptides eluting from the column were ionized by using a
nanospray ESI ion source (Proxeon, Odense) and analyzed on the
QExactive operating in positive-ion mode using electrospray volt-
age 1.9 kV and HCD fragmentation. Each MS/MS  scan was acquired
at a resolution of 35 000 FWHM,  normalized collision energy (NCE)
28, automatic gain control (AGC) target value of 2 × 105, maximum
injection time of 120 ms  and isolation window 2 m/z.
All parallel reaction monitoring (PRM)-based targeted mass
spectrometry methods were designed, analyzed, and processed
using Skyline software version 2.5 [19]. In silico selection of pro-
teotypic peptides was  performed via Skyline using the Homo
sapiens reference proteome available at www.uniprot.org to
exclude non-unique peptides. Frequently modiﬁed peptides, such
as those containing methionine, and peptides containing contin-
uous sequences of R and K (e.g., KR, RK, KK or RR) were avoided.
However, when the inclusion of non-ideal peptides was neces-
sary both unmodiﬁed and M-oxidized peptides as well as peptides
containing a missed cleavage site were analyzed. Synthetic puri-
ﬁed peptides (JPT Peptide Technologies) and tryptic digests from
recombinant proteins were analyzed in a QExactive mass spec-
trometer. Information on retention time and fragmentation pattern
of the top 2–6 ionizing tryptic peptides (2+ or 3+ charge states)
for each protein were used to build a scheduled method with a
retention time window of 5 min. The method was  then used for
peptide quantiﬁcation in the cell lysate pools. A minimum of 2
peptides per protein was  used for quantitative analysis except for
APOBEC3F in which only one of the unique peptides tested was
detectable in the samples. The sum of the integrated peak areas of
the 3–5 most intense fragments was used for peptide quantiﬁca-
tion. Peptide areas for multiple peptides of the same protein were
summed to assign relative abundance to that protein. The error bars
represent the standard deviation of 3 technical replicates.
2.7. Bioinformatics analysis of DNA exome sequencing data
Kataegis regions and somatic mutations for CLL, B-Cell lym-
phoma, ALL, lung adenocarcinoma, and breast, liver, and pancreatic
cancer were downloaded from the supplementary material of a
published study [11]. The kataegis regions within speciﬁc cancer
samples were provided as genomic coordinates into the human
reference genome version 19 (hg19); the somatic mutations were
provided as genomic coordinates in hg19 and nucleotide alter-
ations. We  used the following procedure to create mutational
NA Repair 25 (2015) 60–71 63
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4.4-fold (p<0.001)
2.5
Cell/tissue type Disease
PBMC White blood cells/blood
A431 Epithelial/skin
HEK293T Embryonic kidney NA
DU145 Epithelial/prostate Prostate cancer
T24  Epithelial/bladder Bladder carcinom a
Healthy blood donors
B-cells B-lymphocyte/blood Healthy blood donors
Epidermoid carcinoma
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B-cell/lymphatic
B-cell/lymphatic
B-cell/lymphatic
B-cell/lymphatic
B-cell/lymphatic
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B-NHL
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B-NHL
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B-NHL
B-NHL
DOHH2
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SUDHL4
OCILY3
RAMOS Burkitt lymphoma
SUDHL6
SUDHL5
DAUDI Burkitt lymphoma
Fig. 1. Genomic uracil levels in B-cell lymphoma-/non-lymphoma cell lines and
on white blood cells from peripheral blood l. (A) Quantiﬁcation of genomic uracil
levels (dU/106 nt) by LC–MS/MS in lymphoma cell lines (green), non-lymphoma cell
lines (yellow) and PBMCs or B-lymphocytes isolated from buffy coats from blood
donors (red). Asterisk (*) signiﬁes measurements signiﬁcantly (P < 0.05) different
from average genomic uracil levels in PBMC from three healthy blood donors (Stu-
dent’s T-test). Error bars represent mean and SD of at least two biological replicates.
Cell lines within each group are ordered along the x-axis according to increasing
genomic uracil levels. (B) Overview of cell lines, PBMCs and B-lymphocytes used inH.S. Pettersen et al. / D
ignatures for the kataegis regions for each cancer type. First, for
ach kataegis region, its sample ID and genomic coordinates were
sed to identify the corresponding somatic mutations. Second,
or each somatic mutation, the ﬁve nucleotides centered on the
utated nucleotide were retrieved from the genome sequence.
hird, if the middle nucleotide within the retrieved sequence was  a
urine, the sequence was reverse-complemented such that all the
utations were represented by pyrimidines. Fourth, for each of the
ix possible single nucleotide mutations, the relative occurrence of
ach nucleotide at each position within the retrieved sequences
as computed. These position-speciﬁc relative occurrences were
he mutational signatures.
. Results
.1. High genomic uracil levels in B-cell lymphoma cells
To investigate whether uracil in the genome may  be an impor-
ant factor in lymphomagenesis, we measured genomic uracil in
en B-cell lymphoma cell lines, seven other human transformed cell
ines and in lymphocytes from three healthy human blood donors
Fig. 1A). The origin and major characteristics of cell lines is dis-
layed in Fig. 1B. We  found as much as 72-fold variation in genomic
racil levels between the cell line with the highest uracil content
DAUDI, 4.03 deoxyuridines (dU) per 106 deoxyribonucleosides
nt)) and the cells with the lowest level of genomic uracil (A431,
.056 dU/106 nt). Strikingly, all ten lymphoma cell lines and four of
he other transformed cell lines had signiﬁcantly (P < 0.05) elevated
enomic uracil levels compared to genomic uracil in peripheral
lood mononuclear cells (PBMC) from the mean value for three
lood donors (0.19 dU/106 nt). We  also measured genomic uracil in
-lymphocytes isolated from buffy coats from three healthy donors,
sing a kit for negative selection. The genomic mean uracil level
n these was 0.14 dU/106 nt, with individual values of 0.07, 0.17
nd 0.19 dU/106 nt, respectively. The mean value for the genomic
racil level in B-cell lymphoma cell lines (2.5 dU/106 nt) was 13-fold
nd 18-fold higher than in PBMC and primary B-cells, respectively.
n addition it was signiﬁcantly higher (4.4-fold, P < 0.001) than the
ean for non-lymphoma cell lines (0.57 dU/106 nt). The B-cell lym-
homa cell lines are likely to be exposed to enzymatic untargeted
ytosine deamination by AID throughout the genome, since the
otal number of genomic uracils is in the range 3000–15 000 per
aploid genome (this paper) and the density of genomic uracil in
 region of stimulated B-cells is only ∼0.8 per kb [20]. Some of the
on-lymphoma cancer cell lines had intermediate genomic uracil
evels, clearly higher than normal peripheral blood lymphocytes,
ut lower than most of the B-cell lymphoma cell lines.
.2. AID expression correlates with genomic uracil accumulation
AID has previously been shown to be expressed in several lym-
homa subtypes [21–24] and AID/APOBEC family enzymes were
uggested to contribute to mutational signatures in a number of
ancers by deaminating cytosine to uracil in DNA [11]. We  there-
ore investigated whether expression of AID and/or other APOBECs
ould explain the observed variation in genomic uracil levels in
he cell line panel. We  ﬁrst measured mRNA expression of AID
nd all other APOBEC-family genes by quantitative rtPCR using
APDH as reference gene (Fig. 2A). AID mRNA was  detected in all 17
ell lines, although at highly variable levels, but not in the normal
ymphocytes from blood donors. Furthermore, AID mRNA was sub-
tantially increased in lymphomas with high genomic uracil such
hat AID mRNA had a high positive correlation with genomic uracil
R2 = 0.70, P < 0.0001). By contrast, APOBEC3B, -3D, -3F, and -3G
RNA content did not correlate with genomic uracil level althoughthe study and their origin. B-NHL: B-cell non-Hodgkin lymphoma. (For interpreta-
tion of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
they were expressed in all cell lines as well as in the normal lympho-
cytes (Fig. 2A). mRNA of the other APOBECs (APOBEC1, APOBEC2,
APOBEC3A, and APOBEC) were detected only in some of the cell
lines and mostly at very low levels (data not shown).
Although mRNA expression data is useful as a predictor of pro-
tein expression, it does not always correlate with the actual protein
levels in the cells. Thus, we quantiﬁed AID and the APOBEC proteins
by parallel reaction monitoring using a quadrupole-Orbitrap mass
spectrometer (Fig. 2B). This is a highly selective method allowing
quantiﬁcation of many protein targets in a single sample [25,26].
In agreement with mRNA data, MS  quantiﬁcation revealed higher
amounts of AID protein in lymphoma cells with increased genomic
uracil (Fig. 2B, upper panel). Furthermore, similar to mRNA data
(Fig. 2A, middle panel), APOBEC3B, -3D, -3F and-3G proteins
were expressed in all cell lines (Fig. 2B, middle panel), while
APOBEC1, APOBEC2, APOBEC3A, and APOBEC4 were not detectable
or detected at very low levels (data not shown). In general, protein
levels for AID and the APOBEC proteins (normalized to GADPH pro-
tein) correlated well with mRNA levels (Fig. 2C). As an additional
control, we also quantiﬁed AID by western analysis, which yielded
results similar to the MS  analysis (Fig. 2D). Linear regression
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Fig. 2. Expression of AID and APOBECs, and correlation with genomic uracil. Expression of AID and APOBEC3B, 3D, 3F, and 3G mRNAs measured by qRT-PCR (A) or protein
by  mass spectrometric quantiﬁcation. (B) Lymphoma cell lines are shown in green, non-lymphoma cell lines in yellow, and PBMC in red. Cell lines within each group are
ordered along the x-axis according to increasing genomic uracil levels, as in Fig. 1. mRNA levels have been normalized to GAPDH mRNA, and protein levels to MS signal
counts  per total injected protein. Note that mRNA and protein expression data are in log-scale. Regression plots of genomic uracil (dU/106 nt) vs. AID mRNA and protein levels
are  presented in the lower panels in Fig. 2A and B, respectively. (C) Table of correlation coefﬁcients between mRNA and protein expression for AID and other APOBECs. (D)
Western analysis of AID protein expression with GAPDH shown as a loading control. (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to  the web version of this article.)
Table 1
Regression analysis of genomic uracil levels (linear) vs. AID and APOBEC protein expression (log) normalized to total protein. Bold green indicates signiﬁcant positive
correlation (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.).
All cell lines including PBMC B-cell lymphoma cell lines Non-lymphoma cell lines
R2 P-value R2 P-value R2 P-value
AID 0.65 <0.0001 0.42 0.04 0.00 0.97
APOBEC3B 0.10 0.2089 0.00 0.84 0.00 0.98
APOBEC3D 0.12 0.17 0.00 0.88 0.02 0.79
APOBEC3F 0.01 0.67 0.08 0.44 0.32 0.18
APOBEC3G 0.12 0.14 0.30 0.09 0.00 0.98
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Fig. 3. Genomic uracil levels after stimulation of endogenous AID expression, AID-YFP overexpression, and AID knockdown. (A) Genomic uracil levels in DNA isolated
from  mouse lymphoma cells (CH12F3) stably transfected with AID-YFP or YFP, and confocal microscopy showing subcellular distribution of AID-YFP fusion protein or YFP. (B)
Genomic uracil levels and cell growth of CH12F3 YFP cells and CH12F3 AID-YFP cells prior to stimulation and 48 h after being stimulated to undergo class switch recombination
using  mouse recombinant IL-4, CD40 monoclonal antibody and hTGF- (upper panel) and western blots from one representative experiment showing AID protein expression
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ievels  and -actin as loading control (middle panel). The lower panel shows cell g
rom  at least two  biological replicates. P-values were calculated by a two-tailed Stud
ID-shRNA and control. Western blots shows AID protein expression levels with GA
nalysis of AID western signals against MS  quantitation of AID pro-
ein revealed almost perfect correlation (R2 = 0.95). Importantly,
ID expression signiﬁcantly correlated with genomic uracil also
t the protein level (R2 = 0.65, P < 0.0001) (Fig. 2B, and Table 1),
nd thereby seemed to account for a large part of the variation in
enomic uracil between the cell lines. The correlation was  still valid
hen including only the B-cell lymphoma cell lines in the regres-
ion analysis (Table 1). No signiﬁcant correlations were observed
etween the other APOBEC proteins and genomic uracil (Table 1).
hus, AID was the only APOBEC-family member that correlated
ith genomic uracil in the human cancer cell lines examined here.
.3. AID expression causes several-fold increases in genomic
racil
To investigate whether AID expression signiﬁcantly increases
he overall level of genomic uracil in an otherwise isogenic back-
round, we used stable transfectants of the mouse B-cell lymphoma
ell line CH12F3 expressing AID-YFP fusion protein, or YFP as
ontrol [27]. AID is mostly localized in the cytoplasm (Fig. 3A),
ut is actively imported into the nucleus where it may  access
he genome [12]. We  found that the cells expressing AID-YFP
isplayed an almost six-fold higher level of genomic uracil com-
ared to the YFP control (Fig. 3A). When appropriately stimulated,
H12F3 cells increase endogenous AID expression and have capac-
ty to undergo CSR. Thus next, we investigated whether stimulation of stimulated and unstimulated cells. Graphs represent mean and SD calculated
T-test. (C) Genomic uracil levels in SUDHL5 lymphoma cells stably transfected with
as a loading control.
of these cell lines also increased the level of genomic uracil. A
clear induction of AID and a four-fold increase in genomic uracil
were observed in stimulated CH12F3-YFP cells already after 48 h
(Fig. 3B, upper panel). An increase in genomic uracil was  observed
in the stimulated AID-YFP expressing cells as well, although this
was not signiﬁcant, probably due to the high constitutive expres-
sion AID-YFP. Importantly, the increase in genomic uracil observed
after stimulation could not be ascribed to increased replica-
tive misincorporation of dUMP due to higher proliferation rate
because stimulated CH12F3 cells actually have reduced prolifer-
ation (Fig. 3B, lower panel). Finally, we examined the effect of
knocking down AID using a lentiviral AID shRNA expressing vector.
For this experiment, we  used the human B-cell lymphoma cell line
SUDHL5, which exhibited high constitutive AID expression (Fig. 2B
and D). We found that a 60% knockdown of AID reduced genomic
uracil level by 38% (P = 0.005; Fig. 3C). Taken together these results
strongly support the view that enzymatic cytosine deamination is
the major source of genomic uracil in AID-expressing cells.
3.4. Uracil-DNA repair capacity is inversely correlated with
genomic uracil levelsGenomic uracil is predominantly repaired by base excision
repair (BER), which is mainly initiated by the uracil-DNA glycosy-
lase encoded by the UNG gene [16]. We have previously shown that
UNG deﬁciency in human and mouse cells results in a several-fold
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Fig. 4. Uracil excision activity, expression of uracil DNA glycosylases, and correlation with genomic uracil levels. Note that in all bar graphs cell lines are ordered
according to increasing genomic uracil levels in lymphoma cell lines (green) and non-lymphoma cell lines (yellow), and Y-axes are normalized so that maximum activity
or  maximum protein abundance equals 1. Bars and error bars represent mean and SD of three biological replicates. (A) Relative uracil excision activity from an AID-hotspot
sequence-oligomer containing uracil in U:G context (cleavage assay) and from a nick-translated DNA containing uracil in U:A context (3H-uracil release assay), as indicated
by  color codes. Activity was normalized to total protein. (B) The corresponding correlation between genomic uracil and activity per total protein. (C) Relative uracil excision
activity normalized to activity per cell, and (D) the corresponding correlation with genomic uracil with activity per cell. (E) Western blot of UNG2 and UNG1 in non-lymphoma
and  lymphoma cell lines. (F) Relative abundance of MS-quantiﬁed UNG protein per total protein; (G) Correlation plot of average uracil excision activity vs. relative abundance
of  MS quantiﬁed UNG protein. (H) Relative abundance of MS  quantiﬁed DNA glycosylases SMUG1, TDG and MBD4 and cell doubling times of cell lines; (I) Correlation plot
of  genomic uracil content vs. doubling times of non-lymphoma cell lines and lymphoma cell lines. (J) Contribution of UNG, SMUG1 and TDG through the cell cycle measured by
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ncrease in genomic uracil [15]. The other uracil-DNA glycosylases,
.e. SMUG1, TDG, and MBD4, are thought to be quantitatively less
mportant contributors, at least in proliferating cells [16,28,29].
urthermore, the DNA repair machinery has been shown to protect
gainst AID-induced mutagenesis [30–32]. Therefore, we  measured
racil excision activity of cell free extracts prepared from all cell
ines against oligodeoxyribonucleotides with uracil in a U:G con-
ext. In addition, we measured [3H]-uracil release from calf thymus
NA having uracil in a U:A context. The two different assays gave
imilar activity proﬁles (Fig. 4A). Regression analysis of uracil-
xcision activity (relative to protein content in the cell extracts)
gainst genomic uracil content in the cells demonstrated a nega-
ive correlation (Fig. 4B), which is signiﬁcant (P < 0.05), although
eak. We  also calculated relative uracil excision activity per cell
ince the glycosylases are predominantly nuclear enzymes and the
ells tested vary in size and nucleus-to-cytoplasm ratios (Fig. 4C).
sing these activity values, a stronger correlation with genomic
racil level was observed (Fig. 4D).
The UNG gene encodes both nuclear UNG2 and mitochondrial
NG1, having identical catalytic domains but speciﬁc N-terminal
omains. These isoforms are differently regulated from two pro-
oters [33,34]. Since activity assays measure total activity, we
nalyzed the isoforms by western blots. Nuclear UNG2, which is
he isoform relevant for repair of genomic uracil, was  expressed in
ll cell lines and accounted for approximately half of total UNG in
ost cell lines (Fig. 4E). UNG enzymes are the most active of the
lycosylases, at least in vitro. However, each glycosylase with its
peciﬁc or complementary role may  exert a signiﬁcant impact on
he total level of genomic uracil in vivo. We  therefore quantiﬁed
ll the uracil-DNA glycosylases at protein level by MS.  The relative
bundance of quantiﬁed UNG protein (UNG1 and UNG2) (Fig. 4F)
orrelated strongly with total uracil excision activity (Fig. 4G), in
ccordance with its presumed major role in uracil repair. Similar
o the uracil excision activity, UNG protein per cell also corre-
ated inversely with genomic uracil level when all cell lines were
ncluded in the regression analysis (Table 2). Furthermore, quanti-
ed SMUG1 protein (Fig. 4H) correlated negatively with genomic
racil, although more weakly. Surprisingly, however, SMUG1 was
he only glycosylase that correlated with genomic uracil when only
he B-cell lymphoma group was analyzed (Table 2). In addition,
he AID/SMUG1 protein ratio displayed signiﬁcantly higher corre-
ation with genomic uracil in the B-cell lymphoma group (R2 = 0.65)
ompared to AID alone (R2 = 0.42). No signiﬁcant correlations were
ound for TDG or MBD4 proteins and genomic uracil (Fig. 4H) when
nalyzed separately (Table 2) or in combination with AID or other
lycosylases.
.5. Cell doubling time, genomic uracil content and repair
apacity in cell cycle phases
In cells that do not express AID, one would predict that genomic
racil from misincorporation of dUMP during replication should
esult in increased genomic uracil in cells with short doubling
ime, as suggested previously [35]. Indeed, we observed a signif-
cant inverse relationship between genomic uracil and doubling
ime in non-lymphoma cancer cells (R2 = 0.57; P = 0.048; Fig. 4I).
urthermore, since AID has been shown to act in the G1 phase of
he cell cycle [36–38], one would expect that the lymphoma cell
ines with long doubling times might have higher genomic uracil
evels than those with shorter doubling time. However, we did not
n in vitro assay for complete BER of a single uracil in a deﬁned U:G context. HeLa cells w
epresenting G1/early S-phase, mid  S-phase, G1 and G2 phase, and G1 phase, respectively
he  contribution of each uracil DNA glycosylase was measured by using neutralizing antib
anels are directly comparable since they are generated from the same gel using the sam
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ﬁnd a signiﬁcant positive correlation with doubling time (R2 = 0.27;
P = 0.12), although the curve was  apparently different from that of
the non-lymphoma cell lines (Fig. 4I).
As mentioned above, we  found an inverse correlation between
genomic uracil and both total uracil excision capacity, and with
SMUG1 and UNG protein levels. Nuclear UNG2 expression peaks
during G1/S-phase transition and during S-phase and is expressed
at a lower level in late S-phase, G2 and early G1 [13,39]. In con-
trast, TDG is mainly expressed in the G1 phase of the cell cycle
[13,39]. Thus, TDG might have a role in counteracting untargeted
generation of U:G mismatches by AID in G1, although correlation
studies did not give indications of this. SMUG1 is not cell cycle regu-
lated [40] and may  contribute in all cell cycle phases, but is a rather
slow acting enzyme [16]. To explore the relative contribution of the
uracil-DNA glycosylases in in vitro complete BER of uracil in differ-
ent parts of the cell cycle, we synchronized HeLa cells by double
thymidine block [13], prepared nuclear extracts from the differ-
ent cell cycle phases (monitored by ﬂow cytometry) and applied
an assay for complete BER of U:G mismatches in DNA [14,17,41].
To examine UNG, SMUG1 and TDG separately, we used a combina-
tion of neutralizing antibodies against UNG, SMUG1 and TDG. UNG
was found to be by far the major contributor to initiate BER in the
G1/S transition and in the S phase. Total repair capacity in G2 and
G1 was  somewhat lower than in the S phase, but UNG remained a
major contributor to the initial step in BER-process, although con-
tributing only 1.5–1.7 more than TDG. SMUG1 contributed in all cell
cycle phases, but to a minor degree (Fig. 4J). Thus, a role of TDG and
SMUG1 in BER of U:G mismatches in the G1  phase, and a smaller
role in the S-phase would seem likely from our in vitro data. The
contribution of the different uracil-DNA glycosylases during the
cell cycle is likely to be similar in other human cell lines, includ-
ing B cell lymphoma cell lines, although this has not been formally
demonstrated.
3.6. Lymphomas and CLL carry a distinct AID-hotspot mutational
signature in kataegis regions
Large scale genome sequencing of cancers has produced the
novel observation that several cancers carry localized hypermu-
tation, named kataegis, in small regions that are also associated
with genomic rearrangements. The mutational signatures observed
in most cancer types with kataegis (acute lymphoblastic leukemia
(ALL), lung adenocarcinomas, breast, pancreas, and liver cancer)
suggest an association with APOBEC3 enzymes, with a strong
enrichment of C to T transitions and C to G transversions at
TCA/T sequence contexts [11]. As mentioned, these kataegis pat-
terns might be different from those found in lymphomas and CLL
[11], though this was not explored in detail in their comprehen-
sive paper. We  therefore reanalyzed these exome sequencing data
from kataegis regions of lymphomas and CLL and compared them to
kataegis regions in cancers with typical APOBEC signatures (Fig. 5).
The preferred sequence for C to T mutation in kataegis regions of
B-cell lymphomas and CLL revealed a target sequence that over-
lap with the known AID hotspot motif (WRCY W = A/T, R = purine,
Y = pyrimidine). The general mutational pattern for C to T tran-
sitions in lymphomas and CLL was AGCT, rather than TCA/T for
the other cancer types with kataegis (Fig. 5). This strongly impli-
cates AID-induced genomic uracil formation in the development
of localized hypermutation in B-cell malignancies, in accordance
ere synchronized by double thymidine block, and harvested after 0, 3, 8, and 14 h
, as shown by ﬂow cytometric conﬁrmation of cell cycle distribution in the top row.
odies to UNG, SMUG1, or TDG as indicated. Note that the column size values in the
e substrate. The data points represent mean of independent triplicate experiments.
 the web version of this article.)
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Table  2
Regression analysis of genomic uracil levels (linear) vs. expression of uracil-DNA repair glycosylases (linear) normalized either to total protein or to total protein per cell.
Bold  red indicates signiﬁcant negative correlation (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.).
Per total protein
All cell lines B-cell lymphoma cell lines Non-lymphoma cell lines
R2 P-value R2 P-value R2 P-value
UNG 0.24 0.05 0.01 0.82 0.23 0.28
SMUG1 0.28 0.03 0.41 0.04 0.13 0.43
TDG  0.05 0.35 0.02 0.69 0.13 0.41
MBD4  0.07 0.27 0.02 0.7 0.05 0.63
Per  cell
All cell lines B-cell lymphoma cell lines Non-lymphoma cell lines
R2 P-value R2 P-value R2 P-value
UNG 0.42 0.005 0.05 0.52 0.20 0.31
SMUG1 0.28 0.03 0.16 
TDG  0.22 0.06 0.14 
MBD4  0.00 0.94 0.05 
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Fig. 5. Sequence context of C to T transitions in kataegis regions of lym-
phomas. Sequence analyses are based on exome sequencing data obtained from
[11]. Sequence context of C to T transitions in kataegis regions of lymphomas (n = 21;
1102 single mutation sites) and CLL (n = 15; 290 single mutation sites) showing
an  AID-hotspot consensus sequence ( AGCTN ), where N represents no signiﬁ-
cant difference between A, T, C or G. Comparative analyses of cancers with known
APOBEC signatures in kataegis regions showing an APOBEC consensus signature
(  NTCATN ), from ALL (n = 1; 153 single mutation sites), breast (n = 67; 5021 sin-
gle  mutation sites), liver (n = 15; 175 single mutation sites), lung adenocarcinoma
(n  = 20; 2024 single mutation sites), and pancreas (n = 11; 439 single mutation sites).
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causes widespread cytosine deamination. This is also in accor-
dance with the mutational AID signatures found at many regionsith our genomic uracil measurements and the published associa-
ions between AID and lymphomas [21–24,42–44] and CLL [45,46].
oreover, these 122 lymphoma kataegis regions mapped to 70 dis-
inct 100 kb blocks on 16 chromosomes, further supporting that
nzymatic cytosine deamination by AID is not restricted to the S
egion but occurs genome-wide.0.24 0.06 0.6
0.27 0.32 0.17
0.55 0.00 0.88
4. Discussion
A major ﬁnding in our study is that AID expression is apparently
a predominant source of genomic uracil in B-cell lymphoma cell
lines. The LC–MS/MS method used quantiﬁes genomic uracil as 2′-
deoxyuridine in DNA [15]. The contribution of AID in this process
was not solely made plausible by correlations, but also demon-
strated by physiological induction of the endogenous AID gene,
overexpression of recombinant AID, as well as knockdown of AID
by shRNA. We feel that these results provide convincing evidence
of dC to dU conversion in vivo by AID, which was  considered miss-
ing in a recent review [47]. Furthermore; we found that mutational
signatures in kataegis regions in human B-cell malignancies carry
a distinct AID signature, strongly supporting the concept that AID
is a DNA cytosine deaminase that, when mistargeted cause muta-
tions and eventually B-cell malignancies. The increased genomic
uracil is in general agreement with a recent report on relative
increases in genomic uracil in B-cell lymphoma cell lines express-
ing AID, using an indirect genomic uracil-quantiﬁcation method
[48]. Evidence for targeted generation of uracil in Ig-genes has
been obtained using a ligation-mediated PCR approach [20,49].
AID is normally only expressed in activated germinal center B-
cells [2,50] and at low but detectable levels in early developing
B-cells in the bone marrow [51]. This is apparently a risky pro-
cess because AID strongly promotes the generation of germinal
center-derived lymphomas [22,52,53], in which off-target activity
of AID may  contribute to point mutations and translocations during
lymphomagenesis [31,54,55].
Recently, high-throughput sequencing of complete human
cancer genomes and exomes revealed distinct mutational signa-
tures compatible with mutagenesis by APOBEC-family enzymes
in several common human cancers. This suggests that enzymatic
off-target deamination of DNA-cytosine to uracil might be a major
cause of mutation in human cancers [9–11]. However, direct evi-
dence from measurements of uracil in the cancer genomes has
largely been missing. Importantly, we  found that endogenous
AID-induction in CH12F3 mouse B-cells increases genomic uracil
four-fold, from approximately 750 to 3000 uracils per genome
already after 48 h. It is unlikely that this substantial increase can be
conﬁned to target regions in the Ig genes. Therefore, the increase in
genomic uracil levels following endogenous AID expression indi-
cates that even transiently induced AID expression during CSRin human B-cell malignancy genomes. We  did not observe corre-
lation of genomic uracil with expression of other APOBEC-family
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embers. This does not rule out these as signiﬁcant mutators
n cancer cells, particularly since we only examined seven non-
ymphoma cell lines. Low levels of enzymatic cytosine deamination
ay  be overshadowed by dUMP misincorporation and sponta-
eous cytosine deamination. In addition, the strong effect of AID
n B-cell lymphomas may  obscure contribution of other APOBEC
nzymes. A contribution from APOBECs may  become signiﬁcant
ver time and help drive transformation from normal cell to cancer
ell, as indicated by mutational signatures [11,56].
Although AID expression levels correlated with variation in
enomic uracil in the cells we tested, our results indicate that
dditional factors may  modulate genomic uracil levels. The most
bvious factor would be uracil repair capacity, which varies con-
iderably between cell lines, and dUMP incorporation. We have
reviously shown that UNG is a rate-limiting factor in complete
n vitro BER of genomic uracil [14] although UNG and SMUG1 may
ave complementary roles in uracil repair [16,29,57] and in the
revention of mutagenesis [58]. Studies on UNG−/− cells have doc-
mented an important function for UNG in keeping genomic uracil
evels low [15]. However, the complete absence of any BER fac-
or is a dramatic and rare event, whereas several-fold variation is
ather common, at least in transformed cells. Earlier work demon-
trated that AID-induced mutagenesis was counteracted by UNG,
hich initiates U:G DNA repair [31]. Our data showed that UNG
nd SMUG1 protein levels both correlated inversely with genomic
racil, with UNG showing the strongest correlation across all cells,
hile only SMUG1 correlates signiﬁcantly in the lymphoma cell
ines. Consequently, these results indicate that BER protein lev-
ls do affect genomic uracil. These results do not in themselves,
owever, necessarily reveal the relative importance of individual
lycosylases for in vivo BER. We  therefore made an effort to ana-
yze the role of the glycosylases independently, using an assay for
omplete BER based on nuclear extracts from synchronized HeLa
ells and a plasmid containing a single uracil. The results indicated
hat overall, UNG is the main contributor in initiating BER of uracil,
t least in HeLa cells. However, SMUG1 and TDG may  contribute sig-
iﬁcantly in G1 (and G2), which is also the time when AID is most
ctive.
It is thought that U:G mismatches arising from AID in Ig genes
nd U:G from spontaneous deamination are processed by different
echanisms. Indeed, in order for SHM and CSR to be successfully
arried out, canonical uracil DNA repair may  be locally suppressed.
ne factor contributing to this may  be transcription factor E2A,
hich induces AID [59,60], but represses both UNG-expression and
ts binding to relevant regions in the Ig genes [60]. Furthermore,
53 is actively reduced in germinal center B cells, presumably to
llow mutagenic processing required for antibody maturation [61].
lthough complex, the evidence that AID may  drive carcinogenesis
s well supported. In mice, AID expression was shown to be required
or translocations between Ig loci and proto-oncogenes, a hallmark
f several human B-cell lymphomas [62]. In contrast, AID knockout
ice have fewer translocations [63] and accumulate fewer muta-
ions in genes linked to B cell tumorigenesis [31]. AID expression
as also been shown to confer a mutator phenotype in established
ymphomas [42–44], but the role of AID in cancer progression
emains unsettled [23,64,65]. Interestingly, AID expression has
een reported in numerous cancers of non-B-cell origin, including
reast, prostate, stomach, liver, and lung [66]. It would be inter-
sting to investigate whether aberrant AID expression also confers
igh genomic uracil levels in these cancers. Interestingly, Ung−/−
ice have roughly a 20-fold higher frequency of B-cell lymphoma
ompared with wild-type mice, but no apparent increase in other
ancer types [67,68]. A straightforward explanation for this obser-
ation would be that SMUG1 and TDG together with MMR  may
ompensate for UNG-deﬁciency in most tissues, but not in B-cells
xpressing AID, due to their increased genomic uracil levels.
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A central role for AID-induced mutagenesis in lymphomas is
also indicated by the AID-hotspot signature in the kataegis regions
of a random selection of all lymphomas and CLLs (Fig. 5). We
ﬁnd that the kataegis AID-hotspot signature is not limited to lym-
phomas, but is also present in CLL, which overlaps with the category
small lymphocytic lymphoma. Indeed, AID expression as cause
of an ongoing mutator phenotype has been suggested for both
lymphomas [42–44] and CLL [45,46]. Interestingly, progression of
established cancers through expression of AID was also demon-
strated in other blood cell cancers, such as ALL [69] and chronic
myelogenous leukemia (CML), in which AID expression may lead
to fatal lymphoblastoid crisis [70]. Thus, AID may  be involved in
development and progression of B-cell malignancies, and possibly
only in late stage progression of other blood cell malignancies. This
would be in agreement with the lack of an overall AID signature in
ALL, as observed in our study.
In conclusion, we  have provided strong evidence that AID is a
DNA-cytosine deaminase that due to persistent expression causes
accumulation of genomic uracil in B-cell lymphoma cell lines, as
well as AID mutational signatures in human B-cell malignancies.
Other factors, including expression levels for uracil-DNA glycosyl-
ases and cell doubling time, may  modulate genomic uracil levels,
but AID levels remain the strongest predictor.
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